Morgan Stanley initiated coverage on Bicara Therapeutics with a new price target

10/8/24 7:15:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $35.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCAX

Date	Price Target	Rating	Analyst
5/23/2025	$8.00	Underweight → Equal Weight	Wells Fargo
4/17/2025	$8.00	Underweight	Wells Fargo
2/6/2025	$31.00	Outperform	Wedbush
12/6/2024	$42.00	Buy	H.C. Wainwright
11/5/2024	$48.00	Buy	Rodman & Renshaw
10/8/2024		Overweight	Cantor Fitzgerald
10/8/2024	$35.00	Overweight	Morgan Stanley
10/8/2024		Buy	TD Cowen